Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© 2017 Elsevier Inc. All rights reserved. Clinical trials of multiple pharmacological agents have thus far had more limited success than hypothesized in demonstrating beneficial treatment effects for children; adolescents; and adults with fragile X syndrome (FXS). Other chapters in this edited volume have summarized potential reasons for these limited successes. Here we focus on evaluating the nature of outcome measures that have been used in clinical trials thus far. We emphasize how future trials of both pharmacological and nonpharmacological interventions will require more sensitive and objective measures of neurocognitive functioning; to be developed in close collaboration with stakeholder groups and researchers working on the cognitive; neural; and behavioral profile of individuals with FXS.

Original publication





Book title

Fragile X Syndrome: From Genetics to Targeted Treatment

Publication Date



443 - 455